For cardiovascular complications, there are no established prediction models for patients with type 1 diabetes in the literature. In lieu of such models, we employed prediction models for type 2 diabetes patients from the United Kingdom Prospective Diabetes Study for ischemic heart disease, myocardial infarction, congestive heart failure, and stroke. 10 Hypoglycemic events are a major complication inherent to the treatment of type 1 diabetes. 11 Recent large studies have estimated the risk of severe hypoglycemic events (as defined in 12 ) at 1.1 episodes per patient year in youth with insulin-treated type 1 diabetes. 13 In the hundreds of cases of NDM reported over the last five years after successful conversion to sulfonylureas, there is a consistent major decrease in the incidence of severe hypoglycemia, with only a single episode reported in the literature. We thus assume a rate of 1 episode per 1000 patient years, or 0.001 per patient year.
For diabetic ketoacidosis (DKA), we make a similar assumption that the risk of DKA is extremely low after successful conversion to sulfonylureas. While numerous patients before conversion have been reported to have experienced DKA (similar to type 1 diabetes patients) not a single case has yet been reported after switching off of insulin. We thus assume a rate of 0.01 per patient year based on the hypothetical concern that DKA could occur if a patient stopped all treatment. In contrast, DKA is a major cost of type 1 diabetes that has been suggested to occur 2-10 times per 100 patient-years. In those who are not screened or do not have a treatable mutation we assume a risk based on a recent large prospective study documenting 5.1 episodes of DKA per 100 patient-years. 14 For mortality, first event mortality and diabetes mortality were based again on UKPDS models. 10 Background mortality rates were derived from National Vital Statistics Life Tables. As in prior diabetes modeling exercises, we subtracted the cardiovascular death rates from the overall death rates for the non-diabetes population (based on risk factor data from NHANES 15 and Framingham risk equations 16 ) in order to obtain background death rates for the non-diabetes population. These mortality rates were then increased by 2.75 reflecting the increased risk of background mortality of diabetes patients compared to non-diabetes patients. [17] [18] [19] 
